Primary Objectives:
- To determine the objective response rate of Letrozole when administered to patients with
advanced or recurrent borderline tumors or low-grade epithelial cancers from the ovary ,
fallopian tube or peritoneum.
- To determine the time to tumor progression of patients with advanced or recurrent
borderline tumors or low-grade epithelial cancers from the ovary, fallopian tube or
peritoneum.
- To identify the biological markers to predict response to Letrozole and study the
aspects of the hormones in these types of tumors.